Sectors & IndustriesHealthcareBiotechnology

Best Biotech Stocks to Buy Now (2026)

Top biotech stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +28.50% per year, and are the best biotech stocks to buy now. Learn More.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best biotechnology stocks to buy right now are:

Precigen (NASDAQ:PGEN) is the #1 top biotech stock out of 607 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Precigen (NASDAQ:PGEN) is: Value: C, Growth: A, Momentum: B, Sentiment: B, Safety: D, Financials: C, and AI: B.

Precigen (NASDAQ:PGEN) has a Due Diligence Score of 29, which is 5 points higher than the biotech industry average of 24.

PGEN passed 10 out of 33 due diligence checks and has average fundamentals. Precigen has seen its stock return 284.57% over the past year, overperforming other biotech stocks by 293 percentage points.

Precigen has an average 1 year price target of $14.50, an upside of 100.55% from Precigen's current stock price of $7.23.

Precigen stock has a consensus Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Precigen, 0% have issued a Strong Buy rating, 100% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Protalix Biotherapeutics (NYSEMKT:PLX) is the #2 top biotech stock out of 607 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Protalix Biotherapeutics (NYSEMKT:PLX) is: Value: B, Growth: B, Momentum: C, Sentiment: B, Safety: C, Financials: B, and AI: C.

Protalix Biotherapeutics (NYSEMKT:PLX) has a Due Diligence Score of 50, which is 26 points higher than the biotech industry average of 24.

PLX passed 16 out of 33 due diligence checks and has strong fundamentals. Protalix Biotherapeutics has seen its stock return 62.91% over the past year, overperforming other biotech stocks by 72 percentage points.

Protalix Biotherapeutics has an average 1 year price target of $12.00, an upside of 387.8% from Protalix Biotherapeutics's current stock price of $2.46.

Protalix Biotherapeutics stock has a consensus Buy recommendation according to Wall Street analysts. Of the 1 analyst covering Protalix Biotherapeutics, 0% have issued a Strong Buy rating, 100% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Immucell (NASDAQ:ICCC) is the #3 top biotech stock out of 607 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Immucell (NASDAQ:ICCC) is: Value: C, Growth: A, Momentum: B, Sentiment: C, Safety: C, Financials: B, and AI: C.

Immucell (NASDAQ:ICCC) has a Due Diligence Score of 19, which is -5 points lower than the biotech industry average of 24. Although this number is below the industry average, our proven quant model rates ICCC as a "A".

ICCC passed 6 out of 33 due diligence checks and has weak fundamentals. Immucell has seen its stock return 79.15% over the past year, overperforming other biotech stocks by 88 percentage points.

Out of 7 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 39.8%, which is 33 percentage points higher than the biotech industry average of 6.47%.

Dominari Holdings's dividend payout ratio of -19.1% indicates that its high dividend yield might not be sustainable for the long-term.

Oramed Pharmaceuticals (NASDAQ:ORMP) has an annual dividend yield of 5.81%, which is -1 percentage points lower than the biotech industry average of 6.47%.

Oramed Pharmaceuticals's dividend payout ratio of 9.4% indicates that its high dividend yield is sustainable for the long-term.

Novo Nordisk (Ozempic) (NYSE:NVO) has an annual dividend yield of 2.7%, which is -4 percentage points lower than the biotech industry average of 6.47%. Novo Nordisk (Ozempic)'s dividend payout is not stable, having dropped more than 10% nine times in the last 10 years. Novo Nordisk (Ozempic)'s dividend has shown consistent growth over the last 10 years.

Novo Nordisk (Ozempic)'s dividend payout ratio of 46.1% indicates that its dividend yield is sustainable for the long-term.

Biotech stocks were up 1.15% in the last day, and up 5.64% over the last week. Omniab was the among the top gainers in the biotechnology industry, gaining 37.5% yesterday.

OmniAb shares are trading higher after the company reported better-than-expected Q2 financial results. The company also raised its FY2026 sales guidance above estimates.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued biotech stocks right now are:

Exelixis (NASDAQ:EXEL) is the most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Exelixis has a valuation score of 14, which is 1 points higher than the biotech industry average of 13. It passed 1 out of 7 valuation due diligence checks.

Exelixis's stock has gained 44.61% in the past year. It has overperformed other stocks in the biotech industry by 53 percentage points.

Harmony Biosciences Holdings (NASDAQ:HRMY) is the second most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 57, which is 44 points higher than the biotech industry average of 13. It passed 4 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has gained 12.34% in the past year. It has overperformed other stocks in the biotech industry by 21 percentage points.

Jazz Pharmaceuticals (NASDAQ:JAZZ) is the third most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Jazz Pharmaceuticals has a valuation score of 57, which is 44 points higher than the biotech industry average of 13. It passed 4 out of 7 valuation due diligence checks.

Jazz Pharmaceuticals's stock has gained 128.91% in the past year. It has overperformed other stocks in the biotech industry by 138 percentage points.

70.47% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 50.59% over the next year.

3.04% of biotech stocks have a Zen Rating of A (Strong Buy), 4.34% of biotech stocks are rated B (Buy), 43.17% are rated C (Hold), 39.05% are rated D (Sell), and 10.41% are rated F (Strong Sell).